Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (2024)

IQVIA HOLDINGS INC.

Add to a list

To use this feature you must be a member

Log inSign up

Equities

IQV

US46266C1053

Market Closed - Nyse

Other stock markets

04:00:02 2024-07-09 pm EDT
5-day change 1st Jan Change
213 USD +1.97% Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (2) +2.69% -7.92%
Jul. 09 Evercore ISI Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Outperform Rating MT
Jul. 09 Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07% CI

Financials (USD)

Sales 2024 * 15.47B Sales 2025 * 16.54B Capitalization 38.82B
Net income 2024 * 1.34B Net income 2025 * 1.57B EV / Sales 2024 * 3.27x
Net Debt 2024 * 11.76B Net Debt 2025 * 11.23B EV / Sales 2025 * 3.02x
P/E ratio 2024 *

29.1x

P/E ratio 2025 *

24.4x

Employees 87,000
Yield 2024 *

-

Yield 2025 *

-

Free-Float 70%

More Fundamentals * Assessed data

Latest news about Iqvia Holdings Inc.

Evercore ISI Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Outperform Rating MT
Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07% CI
Alembic Pharmaceuticals Limited Receives USFDA Tentative Approval for Bosutinib Tablets, 100 Mg and 500 Mg CI
Barclays Lowers Price Target on IQVIA Holdings to $255 From $275 MT
Baird Adjusts Price Target on IQVIA Holdings to $241 From $245 MT
IQVIA Launches ?One Home? Clinical Trial Technology Platform, Solves Challenges and Reduces Overload at Sitestes CI
Added health benefits of Wegovy, Zepbound could attract more men, doctors say RE
Goldman Sachs Initiates IQVIA With Buy Rating, $270 Price Target MT
Weight-loss drug forecasts jump to $150 billion as supply grows RE
Transcript : IQVIA Holdings Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM
Iqvia Holdings Inc. Announces Transition of Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks to Become A Senior Advisor to the Chief Executive Officer, Effective May 15, 2024 CI
Stifel Adjusts Price Target on IQVIA Holdings to $288 From $294 MT
UBS Adjusts Price Target on IQVIA Holdings to $295 From $300, Maintains Buy Rating MT
Deutsche Bank Adjusts Price Target on IQVIA Holdings to $275 From $280 MT
Jefferies Adjusts Price Target on IQVIA to $266 From $281 MT

More news

Latest transcript on Iqvia Holdings Inc.

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (3)

IQVIA Holdings Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM

More transcripts

Analyst Recommendations on Iqvia Holdings Inc.

Evercore ISI Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Outperform Rating MT
Barclays Lowers Price Target on IQVIA Holdings to $255 From $275 MT
Baird Adjusts Price Target on IQVIA Holdings to $241 From $245 MT
Goldman Sachs Initiates IQVIA With Buy Rating, $270 Price Target MT
Stifel Adjusts Price Target on IQVIA Holdings to $288 From $294 MT

More recommendations

Press releases Iqvia Holdings Inc.

IQVIA to Announce Second-Quarter 2024 Results on July 22, 2024 BU
IQVIA's SmartSolve eQMS Wins 2024 MedTech Breakthrough Award Best Use of Artificial Intelligence in Healthcare AQ
IQVIA’s SmartSolve® eQMS Wins 2024 MedTech Breakthrough Award “Best Use of Artificial Intelligence in Healthcare” BU
IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites BU
IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses BU

More press releases

News in other languages on Iqvia Holdings Inc.

Eli Lilly eleva en 2.000 millones de dólares previsión de ventas en 2024 por fármaco para adelgazar
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Block, Quanta Services, Nvidia, Home Depot, Nutrien...
Données de santé: Iqvia bondit après des résultats "solides" en 2023
GSK eleva de nuevo sus previsiones anuales impulsada por el fuerte lanzamiento de una vacuna
Neuer RSV-Impfstoff gibt Pharmakonzern GSK Schub - Ziele erhöht

More news

Quotes and Performance

1 day+1.97%
1 week+2.69%
Current month+0.76%
1 month-2.82%
3 months-13.16%
6 months-3.92%
Current year-7.92%

More quotes

Highs and lows

1 week

205.06

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (4)

213.30

1 month

205.06

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (5)

220.48

Current year

205.06

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (6)

261.73

1 year

167.42

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (7)

261.73

3 years

165.75

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (8)

285.61

5 years

81.79

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (9)

285.61

10 years

51.09

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (10)

285.61

More quotes

Managers and Directors - Iqvia Holdings Inc.

Managers TitleAgeSince

Ari Bousbib CEO

Chief Executive Officer 63 16-10-02

Ronald Bruehlman DFI

Director of Finance/CFO 63 20-07-31

James Berkshire COO

Chief Operating Officer 51 17-06-30
Members of the board TitleAgeSince

John Danhakl BRD

Director/Board Member 67 16-10-02

Colleen Goggins BRD

Director/Board Member 68 17-07-26

Ari Bousbib CEO

Chief Executive Officer 63 16-10-02

More insiders

ETFs positioned on Iqvia Holdings Inc.

Name Weight AuM 1st Jan change Investor Rating

LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD

3.67% 0 M€ 0.00% -

LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD

3.45% 0 M€ 0.00% -

FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD

2.92% 1 M€ -.--% -

BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD

2.68% 2 M€ -.--%

More ETFs positioned on Iqvia Holdings Inc.

Quotes

Date Price Change Volume
24-07-09 213 +1.97% 1,123,299
24-07-08 208.9 +0.40% 1,287,096
24-07-05 208.1 +0.62% 1,108,787
24-07-03 206.8 -0.32% 929,729
24-07-02 207.5 -0.49% 936,449

Delayed Quote Nyse, July 09, 2024 at 04:00 pm EDT

More quotes

Company Profile

Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows:- development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes;- development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers;- integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc.Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).

Sector

Calendar

2024-07-22 - Q2 2024 Earnings Release

Related indices

More about the company

Income Statement Evolution

More financial data

Ratings for Iqvia Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B

More Ratings

Analysts' Consensus

Sell

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (15)

Buy

Mean consensus

BUY

Number of Analysts

23

Last Close Price

213USD

Average target price

269.5USD

Spread / Average Target

+26.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

1st Jan change Capi.

IQVIA HOLDINGS INC.

-7.92% 38.07B

MODERNA, INC.

+16.71% 44.63B

LONZA GROUP AG

+42.66% 40.46B

ALNYLAM PHARMACEUTICALS, INC.

+33.09% 32.27B

CELLTRION, INC.

-7.10% 27.3B

ICON PUBLIC LIMITED COMPANY

+14.46% 26.53B

UNITED THERAPEUTICS CORPORATION

+46.73% 14.06B

MEDPACE HOLDINGS, INC.

+34.07% 12.54B

BIO-TECHNE CORPORATION

-7.61% 11.28B

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

-14.62% 10.43B

  1. Stock Market
  2. Equities
  3. IQV Stock
Our Free Content Help you Secure and Increase the Performance of Your Investments Secure my Investments

Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (26)

"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } gaEvent('adspv', 'InvestingChannel_v2', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '40331382');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });
Iqvia Holdings Inc. Stock (IQV) - Quote Nyse- MarketScreener (2024)
Top Articles
Latest Posts
Article information

Author: Dr. Pierre Goyette

Last Updated:

Views: 5979

Rating: 5 / 5 (50 voted)

Reviews: 89% of readers found this page helpful

Author information

Name: Dr. Pierre Goyette

Birthday: 1998-01-29

Address: Apt. 611 3357 Yong Plain, West Audra, IL 70053

Phone: +5819954278378

Job: Construction Director

Hobby: Embroidery, Creative writing, Shopping, Driving, Stand-up comedy, Coffee roasting, Scrapbooking

Introduction: My name is Dr. Pierre Goyette, I am a enchanting, powerful, jolly, rich, graceful, colorful, zany person who loves writing and wants to share my knowledge and understanding with you.